INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 196 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $159,000 | -6.5% | 6,890 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $170,000 | -40.6% | 6,890 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $286,000 | -13.3% | 6,890 | 0.0% | 0.01% | -25.0% |
| Q2 2020 | $330,000 | -24.0% | 6,890 | 0.0% | 0.01% | -33.3% |
| Q1 2020 | $434,000 | -49.2% | 6,890 | 0.0% | 0.01% | -33.3% |
| Q4 2019 | $854,000 | +38.4% | 6,890 | -25.9% | 0.02% | +50.0% |
| Q3 2019 | $617,000 | -16.6% | 9,300 | 0.0% | 0.01% | -20.0% |
| Q2 2019 | $740,000 | -65.0% | 9,300 | -50.8% | 0.02% | -66.7% |
| Q1 2019 | $2,114,000 | -59.3% | 18,900 | -57.9% | 0.04% | -26.2% |
| Q4 2018 | $5,190,000 | +58.0% | 44,900 | +72.7% | 0.06% | -14.1% |
| Q3 2018 | $3,285,000 | +36.9% | 26,000 | -9.1% | 0.07% | +36.5% |
| Q2 2018 | $2,400,000 | -14.4% | 28,600 | -37.3% | 0.05% | -18.8% |
| Q1 2018 | $2,805,000 | +5.3% | 45,600 | 0.0% | 0.06% | +8.5% |
| Q4 2017 | $2,664,000 | +7.7% | 45,600 | +7.0% | 0.06% | +18.0% |
| Q3 2017 | $2,473,000 | -52.1% | 42,600 | 0.0% | 0.05% | -54.1% |
| Q2 2017 | $5,158,000 | +7.1% | 42,600 | 0.0% | 0.11% | +11.2% |
| Q1 2017 | $4,818,000 | -0.1% | 42,600 | -4.1% | 0.10% | -3.9% |
| Q4 2016 | $4,824,000 | -34.0% | 44,400 | 0.0% | 0.10% | -32.5% |
| Q3 2016 | $7,308,000 | +15.4% | 44,400 | 0.0% | 0.15% | +8.6% |
| Q2 2016 | $6,335,000 | +2.7% | 44,400 | -7.5% | 0.14% | +3.0% |
| Q1 2016 | $6,167,000 | +14.1% | 48,000 | +32.6% | 0.14% | +14.4% |
| Q4 2015 | $5,406,000 | -3.9% | 36,200 | +6.8% | 0.12% | -8.5% |
| Q3 2015 | $5,623,000 | -27.7% | 33,900 | +5.3% | 0.13% | -17.3% |
| Q2 2015 | $7,772,000 | -18.2% | 32,200 | -4.5% | 0.16% | -14.3% |
| Q1 2015 | $9,504,000 | +54.2% | 33,700 | -14.7% | 0.18% | +50.4% |
| Q4 2014 | $6,162,000 | – | 39,500 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |